Read more
Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases.
A brief history of each drug's development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement.
This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events.
List of contents
Part I: General Aspects1. Introduction2. Protein and Lipid Kinases3. Kinase Inhibitors4. Adverse Events Part II: Oncotargeted Kinase Inhibitors5. Imatinib6. Gefitinib7. Erlotinib8. Sorafenib9. Sunitinib10. Dasatinib11. Lapatinib12. Nilotinib13. Pazopanib14. Vandetanib15. Vemurafenib16. Crizotinib17. Ruxolitinib18. Axitinib19. Bosutinib20. Regorafenib21. Cabozantinib22. Ponatinib23. Dabrafenib24. Trametinib25. Adatinib26. Idelalisib27. Ibrutinib
Part III: Overview28. Kinase Inhibitors as Adverse Event Inducers29. Kinase Inhibitors as Drug Class Events30. Conclusion and Perspectives
About the author
Professor Emeritus of Immunology and PathologySchool of Medicine and SurgeryCoordinator of the Teachers’ Committee for the Master in Translational BiomedicineUniversita degli Studi di Verona, Italy
